Introduction
Death domain-associated protein (Daxx) is a multifunctional protein that modulates both cell death and transcription [1] . Daxx is present in most cell types and is mainly located in the nucleus. Because previous studies have demonstrated that Daxx can bear both pro-and anti-cell-death activities depending on the stimulus and the cell type [1, 2] , the precise role of Daxx, in particular its ability to promote or hinder cell death, remains controversial. Nevertheless, in lymphocytes, the following observations indicate that Daxx has pro-cell death and/or growth suppressing functions. First, Daxx is induced by type I interferon in pro-B cells and is required for interferon-induced apoptosis [3] .
Second, in Con A-stimulated splenocytes, Daxx up-regulation and interaction with PML correlate with the induction of B-cell apoptosis [4] . Third, CD40-induced proliferation is profoundly reduced in transgenic B-cells over-expressing Daxx [5] . Fourth, analysis of T-cell specific transgenic mice expressing a dominant negative form of Daxx (Daxx-DN) has reveled that Daxx-DN protects activated T-cells from Fas-induced cell death and that T-lymphocytes expressing Daxx-DN exhibit increased proliferative T-cell responses [6] . These findings have indicated that Daxx is a mediator of lymphocyte death and/or growth suppression. However, the precise mechanism of how Daxx affects cell survival remained unclear.
Daxx interacts with and regulates the transcriptional activities of several DNA-binding transcription factors, including ETS1 [7] , PAX5 [8] , Glucocorticoid receptor [9] , RelA [10] , RelB [11] , TCF4 [12] , SMAD4 [13] , C/EBPβ [14] , AIRE [15] and STAT3 [16] . Considering that Daxx binds histone deacetylases [17] , DNA methyltransferases and their associated proteins [18] [19] [20] , and the chromatin-modifying protein α-thalassemia syndrome protein [21, 22] , it seems possible that Daxx regulates 4 cellular processes by regulating transcription of specific genes under different conditions. We have previously shown that Daxx suppresses STAT3-mediated transcriptional activity and has a role in regulating IL-6 family cytokine signaling and gene induction in several cancer cell lines [16] .
The IL-6 family of cytokines utilizes the membrane glycoprotein gp130 as a critical signal-transducing receptor component [23] . Dimerization of gp130 activates the JAK family of protein tyrosine kinases, which phosphorylate and activate cytoplasmic STAT3 [24, 25] . Activated STAT3 dimerizes and translocates to the nucleus where it binds to specific DNA response elements and induces expression of STAT3-regulated genes. STAT3 has been known to play critical roles in the regulation of various cellular events, malignancies and autoimmune diseases [26] [27] [28] . In lymphocyte proliferation, STAT3 activation is responsible for IL-6-dependent T cell proliferation by preventing apoptosis [29] and STAT3 is also indispensable for IL-27-mediated cell proliferation In the present study, we examined the role of Daxx in the gp130/STAT3-mediated cell proliferation signal. We found that Daxx represses STAT3 activity through the inhibition of DNA-binding, thereby inhibiting cytokine-dependent growth and survival of BaF3 cells. Moreover, Daxx also regulates Bcl2 gene expression independently of STAT3 regulation. These results suggest that Daxx exerts growth suppression through the modulation of transcription.
Results

Daxx suppresses gp130/STAT3-dependent cell proliferation
We used an IL-3-dependent mouse pro-B cell line, BaF3-derived BaF-G133, as a model for gp130/STAT3-mediated cell proliferation. It has been reported that, in the absence of IL-3, G-CSF-treatment of BaF-G133 cells induces dimerization of GCSFR/gp130 chimeric receptors causing activation of STAT3 and STAT3-dependent cell growth [32] .
To examine the role of Daxx in gp130/STAT3-mediated cell growth, we introduced siRNA against Daxx (siDaxx) into BaF-G133 cells. Daxx protein levels were significantly reduced by siDaxx while siDaxx had no effect on the levels of STAT3 or β-actin (Fig. 1A) . We then investigated whether this reduction of Daxx in BaF-G133 cells could affect the rate of cell proliferation. After transfection of siRNA, cells were washed in IL-3-free medium and incubated for 48 h in the absence or presence of G-CSF at various concentrations. Silencing of endogenous Daxx by siRNA significantly enhanced the proliferation of BaF-G133 cells at all G-CSF concentrations tested (Fig.   1B ). To further elucidate the role of Daxx in gp130/STAT3-mediated cell growth, we established BaF-G133 transfectants over-expressing Daxx ( Fig. 1C ; BaF-G133/Daxx#3, BaF-G133/Daxx#5, BaF-G133/Daxx#6) and performed growth assays in the presence or absence of either G-CSF. Over-expression of Daxx caused a reduction in cell number when cells were stimulated with G-CSF (Fig. 1D) . These results indicated that Daxx has the ability to suppress the gp130/STAT3-mediated cell growth.
Daxx suppresses cell cycle progression in BaF-G133 cells
To clarify how Daxx regulates cell proliferation, we examined whether 6 gp130-induced cell cycle progression could be affected by knockdown of Daxx. After transfection of siControl or siDaxx, BaF-G133 cells were synchronized in G0/G1 by withdrawing IL-3 and cells were then treated with G-CSF. Cells were fixed and stained with propidium iodide and then DNA content per cell was determined by flow cytometry. As shown in Fig. 2A , BaF-G133 cells transfected with Daxx siRNA exhibited a significant acceleration in gp130-induced cell cycle progression to S and G2/M phases compared with those transfected with control siRNA.
Daxx increases cell death in BaF-G133 cells
Daxx has been reported to positively or negatively regulate cell death [1, 2] . Thus, we tested whether Daxx is involved in the regulation of cell death in BaF-G133 cells.
Leakage of LDH into the medium was used as a marker for membrane breakage and cell death. In cells transfected with control siRNA and cultured without IL-3, G-CSF treatment, in a concentration-dependent manner, increased the number of viable cells (as shown in Fig. 1B ) with a concomitant reduction of cell death, (Fig. 2B , open circle).
Knockdown of endogenous Daxx significantly augmented G-CSF-induced reduction of LDH leakage compared with control cells (Fig. 2B , closed circle).
LDH leakage was increased by about 1.8-fold in Daxx over-expressing transfectants compared with control BaF-G133 cells (Fig. 2C) . In addition, BaF-G133/Daxx#3 cells exhibited an increased percentage of Annexin-V-positive cells compared with control BaF-G133 cells (Fig. 2D ).
These results indicated that Daxx has the ability to suppress cell cycle progression and to increase cell death, thereby controlling cell proliferation in BaF-G133 cells.
Daxx binds to STAT3 and inhibits its activity
We previously showed that Daxx interacts with STAT3 in transiently transfected 293T cells [16] . STAT3 is essential for gp130-mediated G1 to S phase transition in BaF-G133 cells [33] ; therefore, we considered STAT3 to be a potential target of the anti-proliferative function of Daxx. To test whether a Daxx-STAT3 interaction occurs in BaF-G133 cells, we performed co-immunoprecipitation assays (Fig. 3A ). (Fig. 4E) . In addition, a substantial decrease in the binding of RelA and CBP was observed in the BaF-G133/Daxx#3 cells (Fig. 4E) . These results indicated that Daxx negatively regulates RelA and CBP binding to the Bcl2 promoter in BaF-G133 cells.
Over-expression of Bcl2 represses Daxx-mediated cell death
We then analyzed whether Daxx-mediated cell death of BaF-G133 cells was repressed by over-expression of Bcl2. In G-CSF-treated conditions, over-expression of Bcl2 in BaF-G133/Daxx#3 cells decreased LDH leakage to a level comparable with that observed in control BaF-G133 cells (Fig. 5A, left and 5B). Treatment with HA14-1, a small-molecule Bcl2 inhibitor [36] decreased cell viability in a dose-dependent manner in G-CSF-treated BaF-G133 cells (Fig. 5C ), confirming that Bcl2 function contributes to gp130-mediated survival of this cell line. These data indicate that the Daxx-mediated increase in cell death is due, at least in part, to changes in Bcl2 expression in G-CSF-treated BaF-G133 cells. Although Daxx negatively regulated gp130-mediated Bcl2 mRNA induction, it also reduced basal level of Bcl2 expression at the mRNA level. This is likely to suggest that Daxx must have further targets for repression, in addition to activated STAT3. In this regard, we first considered ETS1 to be a candidate, because Bcl2 is induced by over-expression of ETS1 [7] . However, we could not detect any Ets1 mRNA expression in BaF-G133 cells (data not shown), indicating that ETS1 is not involved in the Bcl2 expression in those cells. Bcl2 is also a well known anti-apoptotic target gene of NF-κB.
Daxx can interact with RelA [10] , RelB [11] and CBP [35] , we therefore assessed the effect of Daxx over-expression on Rel and CBP binding to the Bcl2 promoter. Our ChIP experiments using the primers amplifying the Bcl2 promoter region containing the CRE clearly indicated that Daxx negatively regulates RelA and CBP in BaF-G133 cells. In addition, our experiments using a Bcl2 specific inhibitor indicated that gp130-mediated Bcl2 expression is indeed involved in the maintenance of cell survival and that Daxx specifically inhibits the Bcl2 expression. During apoptosis of lymphocytes, an inverse correlation of Daxx and Bcl2 expression levels has been suggested to be important. For example, gene expression profiling of interferon-β-treated progenitor B cells revealed enhanced Daxx expression and nuclear accumulation, with subsequent down-regulation of Bcl2, followed by apoptosis [3] . Another report said that certain mantle cell lymphomas have markedly decreased levels of Daxx expression and exhibit over-expression of Bcl2 and Bcl2l1 [37] . It has also been reported that ectopic over-expression of Daxx down-regulates Bcl2 in malignant lymphocyte Jurkat T-cells and sensitizes cells to the apoptosis-inducing effect of chemotherapeutic agents [38] .
These findings and our results support the idea that Daxx participates in repression, especially that of Bcl2 gene expression and thereby sensitizes cell death. 
G-CSF is a common inducer of the release of hematopoietic progenitor cells (HPC)
from the bone marrow into the peripheral blood [45] . One of the molecular mechanisms underlying this action of G-CSF has been implicated to involve the phosphorylation of JAK1/STAT3 pathway [46] . Daxx has been reported to be expressed in HPC [47] .
Therefore it is possible to speculate that Daxx also could influence G-CSF-mediated mobilization of HPC and the further study will be required to clarify this point.
In summary, we suggest that Daxx has two functional roles corresponding to cell death regulation: STAT3 repression and down-regulation of Bcl2. Our results suggest 14 that the ability of Daxx to repress transcription is relevant to its ability to sensitize cell death. In addition, our finding that STAT3 function can be modulated by Daxx will provide insight into the regulation of various cellular events, malignancies and autoimmune diseases in which STAT3 plays critical roles.
Materials and methods
Cell culture
BaF-G133 cells were a kind gift from Dr. Toshio Hirano (Osaka Univ., Osaka, Japan) and have been described [32] . BaF-G133 cells are derived from an IL-3-dependent mouse pro-B cell line, BaF3, and were maintained in RPMI 1640 medium supplemented with 10% FBS (Trace Biosystems, Sydney, Australia), 10% conditioned medium from WEHI-3B cells as a source of IL-3, 100 U/ml penicillin and 100 µg/ml streptomycin. BaF-G133 cells stably express the chimeric receptor G133, which is Following immunoprecipitation, beads were washed in RIPA buffer (1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl at pH 8.0), followed by RIPA/500 mM NaCl, LiCl buffer (250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl at pH 8.0), and finally, TE buffer. The immunoprecipitated complexes were eluted in a buffer containing 10 mM Tris pH 8.0, 300 mM NaCl, 5 mM EDTA, 0.5% SDS at 65°C for 6 h. The samples were then treated with proteinase K for 1 h, and DNA was purified by phenol/chloroform extraction and ethanol precipitation. Immunoprecipitates were analyzed by PCR. PCR primers were designed to amplify -454/-186 of the JunB promoter, as described previously [50] and to amplify -1560/-1461 of the Bcl2 promoter region containing the CRE as follows: the forward primer was 5'-GCTCAGAGGAGGGCTTTCTT-3' and the reverse primer was 5'-GGCCCGGCCTCTTACTTC-3'. PCR products were electrophoresed on agarose gels and visualized by EtBr staining.
RNA extraction and RT-PCR analysis
Total RNA was extracted from BaF-G133 cells using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). First-strand cDNA was synthesized from 1 µg of total RNA with Revertra Ace reverse transcriptase (TOYOBO, Osaka, Japan) using random nonamers. The cDNA was the template for PCR using Gene Taq polymerase 
